Rest of World Clause Samples
Rest of World. With respect to sales of Licensed Product in all countries of the Territory other than Royalty Major Markets, royalties would be payable, on a Licensed Product-by-Licensed Product basis, in any country starting with the First Commercial Sale of Licensed Product in such country and expiring on a country-by-country basis upon the later of (a) the last to expire Patent owned or Controlled by Novacea that covers the Licensed Product or its use in the Field and provides commercial exclusivity for such Licensed Product, and (b) the end of the first calendar quarter of [*] (the “ROW Royalty Term” and together with the Major Market Royalty Term, the “Royalty Term”), provided, however, that on a country-by-country, Licensed Product-by-Licensed Product basis, the royalties payable by Schering hereunder would be automatically reduced [*] beginning [*] following the date on which unit sales of Generic Products that have entered the market in such country for the then current calendar month are, in the aggregate, greater than [*] percent [*] of the unit sales of the Licensed Product.
Rest of World. (i) The heading of paragraph 7 of Annex 6.08(k) shall be changed to “Other Jurisdictions (other than Switzerland, United States, United Kingdom, India, the Republic of Ireland, Mexico, and, subject to paragraph 6 above, Canada)”.
(ii) In paragraph 7.1 of Annex 6.08(k) of the SAPA, the words: “(other than in Switzerland, United States, United Kingdom, India, the Republic of Ireland and, subject to paragraph 6 above, Canada)” shall be deleted and replaced with: “(other than in Switzerland, United States, United Kingdom, India, the Republic of Ireland, Mexico and, subject to paragraph 6 above, Canada)”
(iii) In paragraph 7.2 of Annex 6.08(k) of the SAPA, the words: “(other than in Switzerland, United States, United Kingdom, India, the Republic of Ireland and, subject to paragraph 6 above, Canada)” shall be deleted and replaced with: “(other than in Switzerland, United States, United Kingdom, India, the Republic of Ireland, Mexico and, subject to paragraph 6 above, Canada)”.
Rest of World. Subject to Section 6.4, (i) AbbVie shall receive [***] of ROW Profit for each Collaboration Program until the aggregate Row Profit received by AbbVie reaches [***] (the “ROW Profit Threshold”) for such Collaboration Program; and (ii) thereafter Licensor shall receive [***] of ROW Profit attributable to Licensed Products for such Collaboration Program, and AbbVie shall retain [***] of ROW Profit attributable to Commercialization of Licensed Products. For clarity it is understood that the amount of the ROW Profit Threshold is based on the anticipated losses to be incurred by AbbVie in launching the first Licensed Product for the applicable Collaboration Program in all of the non-US Major Markets, and that such launches will be made [***], the same will be determined pursuant to Section 13.7.4 below. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
Rest of World. Subject to Sections 3.1 and 3.2 above, in all markets other than [***], [***]:
(a) Each Party may use, sell, offer to sell, market, distribute, resell, license, or otherwise dispose of any ATG connectivity solution.
(b) Gogo hereby grants to Airspan the non-exclusive right to use, sell, offer to sell, market, distribute, resell, license, or otherwise dispose of any ATG connectivity solution that incorporates or uses know-how developed in connection with this Agreement or any SOW or Gogo intellectual property and Airspan will pay [***] derived from the sale of ATG-related equipment or services in accordance with the scope of this Section 3.3.
(c) Airspan hereby grants to Gogo the non-exclusive right to use, sell, offer to sell, market, distribute, resell, license, or otherwise dispose of any ATG connectivity solution that incorporates or uses Airspan intellectual property or know-how developed in connection with this Agreement or any SOW.
Rest of World. Subject to the terms and conditions of this Agreement, effective as of the CGI License Date and the JTI License Date, as the case may be, XT hereby grants to each of CGI and JTI a co-exclusive license or sublicense, as the case may be, under the Licensed Technology, to make and have made Product anywhere in the world for use, sale, import or other distribution in the Rest of the World in the Licensed Field. Such co-exclusive licenses or sublicenses shall be co-exclusive even as to XT and shall include the co-exclusive right to grant and authorize sublicenses for exploitation within the Rest of the world (excluding any rights to the Mice as defined in the Master Research License and Option Agreement)
Rest of World. Delivery for 1 hat: o 1st Class recorded delivery (we will email you the number) - £10.05 Delivery for up to 3 hats: 1st Class recorded delivery (we will email you the number) - £12.90 Delivery for 4 - 7 hats: o Royal Mail recorded delivery (with compensation up to £500 – We will email you the number) - £18.60 Delivery for 8 – 11 hats: o Royal Mail recorded delivery (with compensation up to £500 – We will email you the number) - £30.00 All prices accurate from the Post Office website as of 21 October 2014. Please contact us on ▇▇▇▇ ▇▇▇▇▇▇▇ or ▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇.▇▇ for a quote on any orders larger than those stated above.
Rest of World. For transactions with Tenable Network Security Ireland Limited, this Agreement and any issues, disputes or claims arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) (“Disputes”) shall be governed by, and construed in accordance with, the laws of Ireland. All Disputes arising out of or relating to this Agreement shall be subject to arbitration within the meaning of the Arbitration ▇▇▇ ▇▇▇▇ or any legislation amending or repealing that act and shall be an arbitration conducted in Dublin, Ireland in the English language and shall be governed by the Arbitration ▇▇▇ ▇▇▇▇. Notwithstanding the foregoing, nothing in this Agreement shall limit the right of either party to seek any injunctive, equitable or other interlocutory relief as it may be entitled to in the Courts of Ireland.
Rest of World. [*] of the Net Proceeds received by Xenova from the commercialization and sale of the Finished Product in the Field in any country or regulatory jurisdiction outside the Development Territory after Regulatory Approval has been obtained therefor; and
Rest of World. Lilly shall pay one hundred percent (100%) of the Commercialization Costs for Commercialization of Products in all countries in the Territory outside the U.S. and Amylin shall pay 0% of such Commercialization Costs, with the sole exception of OUS Non-BID Commercialization Trial Costs which shall be allocated 80% to Lilly and 20% to Amylin.” ***CONFIDENTIAL TREATMENT REQUESTED Lilly will prepare and deliver to Amylin, in addition to and concurrently with the [***] composite reports due pursuant to Section 4.9(a), a separate composite report of OUS Non-BID Commercialization Trial Costs substantially the same in scope, content and format to the [***] reports of Development Costs due pursuant to Section 4.3(b), and the amounts reported in such composite report of OUS Non-BID Commercialization Trial Costs shall be aggregated with the amounts reported in the composite reports specified in Section 4.9(a) and included in the calculation of periodic settlement payments between the Parties contemplated by Section 4.9(a). The parties recognize that Lilly does not formally track time spent by OUS FTE’s on Development matters versus time spent by the same individuals on Commercialization matters so that good faith allocations of FTEs between the categories of Non-BID Commercial Trial Costs and Non-BID Development Trial Costs may be necessary.
(c) Costs for OUS Studies Utilized in U.S.
(i) The Parties recognize that data from certain clinical, health outcomes or other studies undertaken for Development or Commercialization purposes relating to countries outside the U.S. (an “OUS Study”) may generate data that could also be utilized for U.S. purposes. Accordingly, the Parties agree as follows:
a. Except with respect to any Required Study, the Global Development and Commercialization Committee (“GDCC”) shall, prior to the initiation of any OUS Study, review whether such OUS Study is also expected to generate data that will be utilized for U.S. purposes. If the GDCC agrees that the OUS Study will also be used for U.S. purposes, (a “Dual Use Study”) then the expense of such Dual Use Study shall be shared in accordance with the Dual Use Cost Allocation. In all other cases, the expenses of the OUS Study shall be shared in accordance with the OUS Study Cost Allocation, but shall be subject to possible later recharacterization as provided in paragraph (d) below. The Parties agree that their respective representatives to the GDCC will act in a reasonable manner with respect to a...
Rest of World. For purposes of the payment by Novartis to Tanox of royalties for the Rest of World as provided under the Agreement and this EA Financial Appendix, the presentation of results of operations of Novartis for the Rest of World will be based on Novartis’ financial information for the Rest of World for the applicable period in the reporting format depicted as follows: Gross Sales (ROW) less ***** = Net Sales (ROW).